Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release.
about
Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammationSynchronous recruitment of epigenetic modifiers to endotoxin synergistically activated Tnf-α gene in acute kidney injuryParenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy.Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.Iron therapy for renal anemia: how much needed, how much harmful?A randomized trial of intravenous and oral iron in chronic kidney diseaseComparison of tissue-selective proinflammatory gene induction in mice infected with wild-type, DNA adenine methylase-deficient, and flagellin-deficient Salmonella enterica.Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.Risk of infection with intravenous iron therapy.Do high blood hepcidin concentrations contribute to low ferritin levels in young tennis players at the end of tournament season?Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney diseaseIron deficiency anemia in chronic kidney disease: Uncertainties and cautions.Fe allocation in liver during early stages of endotoxemia in Fe-overload rats.What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Emerging Evidence on the Safety of Intravenous Iron in Chronic Kidney Disease.TNF-α-mediated cardiorenal injury after rhabdomyolysis in rats.
P2860
Q26830874-494D849E-B24D-4884-BBE0-979EB414B9EFQ27310345-C21D0236-1D2B-479D-872A-4E9B883A31E6Q34085240-7A7AC64A-7F12-4CD1-9C5F-43C029CEA8A0Q34255473-964B2975-663F-4588-B1CB-34A8028A97E5Q35631492-93980155-D5BF-48BE-B348-E6142995954EQ35650627-A0B6AC0E-73A9-4208-B597-E721CC51777DQ36108862-579A14AD-CFA9-4532-B220-87D39B3E9075Q36314053-8CA7C5FE-3783-415A-AC02-06F7CD12EE4CQ36577123-D70FFFCA-81FA-4A78-BD51-E607AB05A3B7Q36897822-3616464C-C224-4EA7-860B-EA54A9BF7E82Q37144201-D7C2091E-7D36-4DC5-A793-C9EF465F9D06Q37195412-6CF283C8-C272-4C24-A6E1-FA8D9A96FB1CQ38839971-FB72AAF6-91D3-437A-B361-248191AD9D66Q45140455-21D8B987-0C83-48D7-BBDA-BB5BAF7E2AE4Q48040293-64AD7D83-4EC4-451E-A6C4-A012E914913FQ53004631-AB924DE7-9D1E-412C-82EB-AA81186906C1
P2860
Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Parenteral iron compounds sens ...... duction and TNF-alpha release.
@en
Parenteral iron compounds sens ...... duction and TNF-alpha release.
@nl
type
label
Parenteral iron compounds sens ...... duction and TNF-alpha release.
@en
Parenteral iron compounds sens ...... duction and TNF-alpha release.
@nl
prefLabel
Parenteral iron compounds sens ...... duction and TNF-alpha release.
@en
Parenteral iron compounds sens ...... duction and TNF-alpha release.
@nl
P2093
P2860
P1476
Parenteral iron compounds sens ...... duction and TNF-alpha release.
@en
P2093
A C M Johnson
Richard A Zager
S Y Hanson
Steve Lund
P2860
P304
P356
10.1152/AJPRENAL.00342.2004
P577
2004-10-19T00:00:00Z